真性红细胞增多症患者对羟基脲治疗耐药的预测:一项在前瞻性介入性IV期试验(HU-F-AIM)中验证的机器学习研究(PV-AIM)
红细胞分布宽度(RDW)和血红蛋白(HGB)与HU耐药关联最强,二者协同作用可用于血栓栓塞风险分层。基于PV-AIM结果启动开放标签、前瞻性、单臂、介入性IV期HU-F-AIM研究验证预测生物标志物。
要点
- RDW和HGB是与羟基脲耐药关联最强的基线预测标志物。
- RDW与HGB存在协同交互作用,可用于血栓栓塞风险分层。
- 基于PV-AIM结果已启动前瞻性IV期HU-F-AIM研究进行验证。
核心结论
- 利用常规临床数据可构建羟基脲耐药早期检测框架,促进及时干预。
- 研究结果强调PV个体化治疗的重要性,并凸显机器学习提升预测准确性的价值。
- 提出区分真正分子耐药与临床耐药的更新术语,可能提示需要替代治疗策略。
研究设计与样本
- PV-AIM项目的一部分,采用机器学习技术分析Optum®电子健康记录数据库的真实世界证据。
- 基于PV-AIM结果启动开放标签、前瞻性、单臂、介入性IV期研究HU-F-AIM,评估羟基脲耐药/不耐受。
主要发现
- 关键预测标志物包括红细胞分布宽度(RDW)和血红蛋白(HGB),与羟基脲耐药关联最强。
- 识别出RDW与HGB之间的协同交互作用,可实现血栓栓塞风险分层。
- 羟基脲耐药在相当一部分患者中发生,导致发病率增加并需要替代治疗。
临床怎么用
- 预测生物标志物的验证可能有助于识别有羟基脲耐药风险的患者,这些患者可能从替代治疗选项中获益。
- 可能避免羟基脲治疗期间持续放血,该做法在高危PV中常见,与早期疾病进展和血栓栓塞并发症增加相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased thromboembolic (TE) risk and hematologic complications. Hydroxyurea (HU) serves as the most frequently used first-line cytoreductive therapy worldwide; however, resistance to HU (HU-RES) develops in a significant subset of patients, leading to increased morbidity and necessitating alternative treatments. This study, part of the PV-AIM project, employed machine learning techniques on real-world evidence (RWE) from the Optum® EHR database containing 82.960 PV patients to identify baseline predictors of HU-RES within the first 6-9 months of therapy. Using a Random Forest model, the study analyzed data from 1850 patients, focusing on laboratory parameters and clinical characteristics. Key predictive markers included red cell distribution width (RDW) and hemoglobin (HGB), showing the strongest association with HU-RES. A synergistic interaction between RDW and HGB was identified, enabling TE risk stratification. This study provides a robust framework for early detection of HU-RES using readily available clinical data, facilitating timely intervention. These findings underscore the importance of personalized treatment approaches in managing PV and highlight the utility of machine learning in enhancing predictive accuracy and clinical outcomes. Based on the results of PV-AIM we initiated an open-label, prospective, single-arm, interventional, phase IV study (HU-F-AIM) evaluating HU-resistance/intolerance. Validation of predictive biomarkers may facilitate identification of patients at risk of HU resistance who may benefit from alternative treatment options, possibly preventing ongoing phlebotomy during HU treatment, a frequent therapeutic choice in high-risk PV associated with early disease progression and increased thromboembolic complications. We propose an updated terminology that differentiates between true molecular resistance and clinical resistance, that may indicate the requirement for alternative therapeutic strategies.
引用
- Heidel FH, De Stefano V, Zaiss M, et al. Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM). Leukemia. 2025. PMID: 40281326. doi:10.1038/s41375-025-02623-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。